Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
An inherited cancer-predisposition mechanism distinct from that of mutations affecting tumour-suppressor proteins and oncoproteins
Findings from genomic analysis in a rapid autopsy cohort study
Findings from 2-year analysis of CodeBreaK 100 study
Findings from the CUTALLO study
Extended indication concerns the treatment of melanoma in adolescents 12 years of age and older
Findings from the DESTINY-Breast02 study
Findings from the SUNLIGHT study
Findings from the POSITIVE study
It is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a Bruton’s tyrosine kinase inhibitor
Substantial heterogeneity observed in cancer screening programme organisation and performance
Findings from the KRYSTAL-1 study cohort excluding NSCLC and CRC
Findings from the QuANTUM-First study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
